Horwitz Steven M, Olsen Elise A, Duvic Madeleine, Porcu Pierliugi, Kim Youn H
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
J Natl Compr Canc Netw. 2008 Apr;6(4):436-42. doi: 10.6004/jnccn.2008.0033.
The NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Disease were recently revised to include recommendations for treating mycosis fungoides and Sézary syndrome. These uncommon lymphomas require a specialized evaluation and use a unique TNMB staging system. Unlike the other forms of non-Hodgkin's lymphomas, stage overwhelmingly determines prognosis and defines radically different treatment approaches. For patients with early-stage disease, initial treatment with skin-directed therapies is preferred, and many patients never require systemic therapy. For patients with refractory or advanced-stage disease, biologic therapies are often the first choices, whereas chemotherapies are reserved for later in the disease course. Many milder therapies may be repeated several times in the disease course, and maintenance and tapering strategies are common. This article also discusses the emerging role of allogeneic stem cell transplantation.
美国国立综合癌症网络(NCCN)肿瘤学临床实践指南:非霍奇金淋巴瘤最近进行了修订,纳入了蕈样肉芽肿和塞扎里综合征的治疗建议。这些罕见淋巴瘤需要进行专门评估,并采用独特的TNMB分期系统。与其他形式的非霍奇金淋巴瘤不同,分期在很大程度上决定预后,并定义了截然不同的治疗方法。对于早期疾病患者,首选皮肤定向疗法进行初始治疗,许多患者从未需要全身治疗。对于难治性或晚期疾病患者,生物疗法通常是首选,而化疗则留待疾病进程后期使用。许多较温和的疗法在疾病进程中可能会重复多次,维持和减量策略很常见。本文还讨论了异基因干细胞移植的新兴作用。